[Radioprotective Properties of NO-Synthase Inhibitor T1023: I. Indicators of Radioprotective Activity and Interaction with Other Radioprotectors]. 2015

M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov

The study of radioprotective activity of NO-synthase inhibitor, N-S-isothiourea derivative T1023 showed that this compound has a significant therapeutic range of radioprotective activity (5.5-6.0) and its optimal radioprotective dose is 1/4 LD16. The value of its Radiation Dose-Reduction Factor totaled 1.4-1.8. We have demonstrated a pronounced pharmacodynamic interaction of T1023 with some known radioprotectors. The character of the interaction was determined by its vasoactive properties. Combined use of T1023 and cystamine, which causes a decrease in vascular tone, was accompanied by a statistically significant weakening of the radioprotective effect. But, the combined use of T1023 with serotonergic and adrenergic radioprotectors having a pressor action caused a statistically significant increase in the radioprotective effect. Moreover, T1023 combined with such radioprotectors caused the synergistic radioprotective effect even when used at small doses that do not have any radioprotective effect alone. The findings suggest that NOS inhibitors can be effective radioprotectors and are able to create new opportunities for the development of safer radioprotective agents. The very same compound T1023, according to current criteria of pharmacological screening, is certainly promising for further investigations.

UI MeSH Term Description Entries
D011829 Radiation Dosage The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv). Sievert Units,Dosage, Radiation,Gray Units,Gy Radiation,Sv Radiation Dose Equivalent,Dosages, Radiation,Radiation Dosages,Units, Gray,Units, Sievert
D011833 Radiation Injuries, Experimental Experimentally produced harmful effects of ionizing or non-ionizing RADIATION in CHORDATA animals. Experimental Radiation Injuries,Injuries, Experimental Radiation,Experimental Radiation Injury,Radiation Injury, Experimental
D011835 Radiation Protection Methods and practices adopted to protect against RADIATION. Protection, Radiation
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D003538 Cystamine A radiation-protective agent that interferes with sulfhydryl enzymes. It may also protect against carbon tetrachloride liver damage. Cystineamine,Decarboxycystine,Diaminodiethyldisulfide,2,2'-Dithiobisethanamine,Cystamine Calcium Salt,Cystamine Diacetate,Cystamine Dihydrobromide,Cystamine Dihydrochloride,Cystamine Hydrobromide,Cystamine Hydrochloride,Cystamine Sulfate,Cystamine Sulfate (1:1),Cysteinamine Disulfide,Cystinamin,2,2' Dithiobisethanamine,Calcium Salt, Cystamine,Diacetate, Cystamine,Dihydrobromide, Cystamine,Dihydrochloride, Cystamine,Disulfide, Cysteinamine,Hydrobromide, Cystamine,Hydrochloride, Cystamine,Sulfate, Cystamine
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005720 Gamma Rays Penetrating, high-energy electromagnetic radiation emitted from atomic nuclei during NUCLEAR DECAY. The range of wavelengths of emitted radiation is between 0.1 - 100 pm which overlaps the shorter, more energetic hard X-RAYS wavelengths. The distinction between gamma rays and X-rays is based on their radiation source. Gamma Wave,Gamma Radiation,Nuclear X-Rays,Radiation, Gamma,X-Rays, Nuclear,Gamma Radiations,Gamma Ray,Gamma Waves,Nuclear X Rays,Nuclear X-Ray,Ray, Gamma,Wave, Gamma,Waves, Gamma,X Rays, Nuclear,X-Ray, Nuclear
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013890 Thiourea A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.

Related Publications

M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 1979, Radiobiologiia,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 1993, Radiation research,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 2003, Radiatsionnaia biologiia, radioecologiia,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 1979, Radiobiologiia,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 2001, Radiatsionnaia biologiia, radioecologiia,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 1999, Biofizika,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 2013, Radiatsionnaia biologiia, radioecologiia,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 1974, Radiobiologiia,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
January 2012, Journal of inorganic biochemistry,
M V Filimonova, and L I Shevchenko, and V M Makarchuk, and E A Chesnakova, and O S Izmest'eva, and T S Korneeva, and A S Filimonov
March 2018, The Journal of biological chemistry,
Copied contents to your clipboard!